Under Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian. Barry McKenzie, MD St. Vincent Healthcare

Size: px
Start display at page:

Download "Under Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian. Barry McKenzie, MD St. Vincent Healthcare"

Transcription

1 Under Triage and Anticoagulants in the Geriatric Trauma Population Fragile Must be Italian Barry McKenzie, MD St. Vincent Healthcare

2 Objectives Describe the increasing frequency of trauma patients being elderly. Understand the consequences of under activation in the geriatric trauma patient. Describe some of the challenges in identifying a geriatric trauma patient. Discuss the various forms of common oral anticoagulants. Review existing means and agents for reversal of common anticoagulants.

3 Data What is geriatric? Age - 55? 65? 70? 80? EAST guidelines For all ISS and body region injured Age Sharp increase in mortality Age 75 Doubled mortality

4 Data % of all traumas victims are > 65 33% of all trauma care costs are spent on elderly patients Trauma care costs 3 times as much for an elderly person compared to a younger person Undertriage of the elderly two-fold increase in risk of death

5

6 Issues with Geriatric Trauma Increased morbidity and mortality across all injuries They are old why try? Many will return to pre-injury status with appropriate management Functional status becomes critical outcome measure Presenting GCS

7 Who is a Trauma? 69 year old female struck by a vehicle in Costco parking lot. She has GCS of 13 and left chest pain. 92 year old male who fell and struck her night stand going to the bathroom at night. He now has headache and hip pain. 76 year old female tripped while walking and struck her chin. Now with bilateral upper extremity paresthesia. 67 year old male farmer fell out of his tractor. He is mad because he got started late due to the local Coumadin clinic running behind.

8 Issues with Identifying Geriatric Trauma Patients Elderly normal physiology Chest and pulmonary function Neurological baseline Anticoagulants

9 Blood Pressure

10 Chest Injuries Bulger et al. Geriatric trauma patients and chest wall injuries 3-4 rib fractures Pneumonia increase 31% Mortality 19% More than 6 rib fractures 33% mortality 51% occurrence of pneumonia For each additional rib fracture Mortality increased by 19% Risks of pneumonia increased by 27%

11 Neurological Status Alteration in mental status Delirium Dementia Traumatic Brain Injury Organ failure leading to decreased organ perfusion Shock Quick escalation of injury due to anticoagulation Less endurance Airway management

12 GCS and Mortality

13 Under Triage JACS Stanford University study 6,015 patients Age 55 and older Called 911 and admitted to hospital Records reviewed Mortality rates Trauma center 5.7% Nontrauma center 9% 32.8% met criteria for referral to trauma center (ISS > 15) Less procedures performed at nontrauma centers 1 day less in the trauma center

14 Ohio Geriatric Trauma Triage > 70 years old considered geriatric trauma patient GCS < 15 with evidence of traumatic brain injury Systolic BP < 100 mmhg Falls with evidence of TBI (even from standing height) Pedestrian struck by motor vehicle Multiple body regions injury Known or suspected proximal long bone fracture in MVC

15 Montana Geriatric Activation GCS < or equal to 13 with known/suspected TBI Decreased LOC Unequal pupils Persistent headache Blurred vision Nausea or vomiting Change in neurological status Systolic BP <110 mmhg or absent radial/carotid pulse Known/suspected proximal long bone fx with hx of MVC Multiple body regions injured Auto vs pedestrian Fall from any height with evidence of TBI Co-morbidities Anticoagulation agents

16 Scary News Over 6 million people on anticoagulants US population 326 million 30 million warfarin prescriptions written annually Over 2/3 of Medicare patients with atrial fibrillation are on warfarin Once anticoagulants start they stay

17 Anti-coagulation and Trauma Alert Protocol Triage parameters Age > or equal to 65 Anticoagulation agents GCS < or equal to 13 Hx of head within past 24 hours Response protocol ED response team (Provider, RN and lab) 15 minutes Coagulation lab tests and INR completed within 20 minutes Stat/priority head CT completed within 30 minutes

18 Anticoagulants Vitamin K antagonists Warfarin Antiplatelet agents Clopidogrel (Plavix) ASA Direct oral thrombin inhibitors Dabigatran (Pradaxa) Direct oral factor Xa inhibitors Apixaban (Eliquis) Ribaroxaban (Xarelto) Edoxaban (Savaysa) Indirect factor Xa inhibitors Fondaparinux (Arixtra)

19

20 Coumadin Inhibits Vitamin K dependent clotting factors II, VII, X Protein C & S Affects extrinsic & common pathways

21 Coumadin Reversal Vitamin K Four factor prothrombin complex concentrates (PCC) Rapid reversal of vitamin K antagonists Plasma derived products Kcentra, CSL Behring Expensive (single dose of Kcentra for 80 kg patient - $5,080) Effects can wear off Fresh frozen plasma

22 Plavix (clopidogrel) Inhibits function of ADP associated with platelet activation Most literature associated with ICH Platelets transfusion Desmopressin (DDAVP; promotes VWF as well as Factor VIII) Some discussion of steroids No great answer

23 Direct Thrombin Inhibitors Dabigatran (Pradaxa) Direct inhibitor of thrombin Prevents conversion of fibrinogen to fibrin Reversal Idarucizumab (Praxbind) Monoclonal antibody Binds to drug $3,000 to $4,000

24 Factor Xa Factor Xa is central to the propagation of coagulation In combination with cofactors bound to activated platelets, Factor Xa amplifies coagulation by converting prothrombin to thrombin

25 Factor Xa Inhibitors Direct Factor Xa inhibitor Rivaroxaban (Xarelto) Apixaban (Eliquis) Edoxaban (Savaysa) Indirect Factor Xa inhibitor Binds antithrombin - accelerates its inhibition of factor Xa. Fondaparinux (Arixtra)

26 Factor Xa inhibitors Reversal agent for Xarelto and Eliquis Andexxa FDA approval May 2018 Low and high dose regiment $25,000 to $50,000 projected figures for cost of treatment Drug cost only administration cost to patient? Only in 10 to 20 institutions throughout the US

27 Local challenges

28 Who is a Trauma? 69 year old female struck by a vehicle in Costco parking lot. She has GCS of 13 and left chest pain. 92 year old male who fell and struck her night stand going to the bathroom at night. He now has headache and hip pain. 76 year old female tripped while walking and struck her chin. Now with bilateral upper extremity paresthesia. 67 year old male farmer fell out of his tractor. He is mad because he got started late due to the local Coumadin clinic running behind.

29 Summary The geriatric population is becoming more and more the trauma population. Identifying the geriatric trauma patient requiring trauma activation can be difficult and likely requires separate activation criteria. Under activation of the geriatric trauma patient is a growing issue and has a negative effect on outcome. A growing number of patients are on some form anti coagulation and trauma providers need to be familiar with the various agents. Reversal agents for new anti coagulants exist but can be expensive and create a resource utilization challenge. Open discussions need to happen regarding maintenance of anticoagulants after trauma event.

30 Questions?

31 References ACS TQIP Geriatric Trauma Management Guidelines Bulger EM, Arneson MA, Mock CN, Jurkovich GJ. Rib fractures in elderly. J Trauma. 2000;48: ems.ohio.gov Jacobs, Plaisier, Barie, Hammond, Holevar, Sinclair, Scalea and Wahl (EAST Practice Management Guidelines Work Group, Pracitice Management Guidelines of Geriatric Trauma: The EAST Practice Management Guidelines Work Group, J Trauma. 54(2): , February Jürgen Koscielny and Edita Rutkauskaite, Rivaroxaban and Hemostasis in Emergency Care, Emergency Medicine International, vol. 2014, Article ID , 9 pages, doi: /2014/ Meadow, Dierks, Williams and Zacko, The Emergent Reversal of Coagulopathies Encountered in Neurosurgery and Neurology: A technical note, CM&R Rapid Release, November 7, 2014 Staudenmayer, Hsia, Mann, Spain and Newgard, Triage of Elderly Trauma Patients: A Population-Based Perspective, Journal of the American College of Surgeons, 2013; 217 (4): 569

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol

Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Adult Reversal of Anticoagulation and Anti-platelet Agents for Life- Threatening Bleeding or Emergency Surgery Protocol Page Platelet Inhibitors 2 Aspirin, Clopidogrel (Plavix), Prasugrel (Effient) & Ticagrelor

More information

Guideline for Treatment of Head Injury in the Anticoagulated Patient

Guideline for Treatment of Head Injury in the Anticoagulated Patient Guideline for Treatment of Head Injury in the Anticoagulated Patient GUIDELINE: GUIDELINE FOR TREATMENT OF HEAD INJURY IN THE ANTICOAGULATED PATIENT BACKGROUND: Chronic anticoagulation therapy is used

More information

Geriatric Trauma Resuscitation: Lessons from a Geriatric Trauma Surgeon

Geriatric Trauma Resuscitation: Lessons from a Geriatric Trauma Surgeon Geriatric Trauma Resuscitation: Lessons from a Geriatric Trauma Surgeon Aurelio Rodriguez, M.D., FACS Conemaugh Memorial Medical Center Trauma Center Johnstown, PA Demographics The fastest growing age

More information

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism

Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process

More information

Advances in Anticoagulation

Advances in Anticoagulation May 18, 2017 Advances in Anticoagulation Wei Ling Lau, MD Assistant Professor, Nephrology University of California, Irvine Talk Outline High stroke risk in CKD population Warfarin off-target effects on

More information

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade

More information

Anticoagulation Task Force

Anticoagulation Task Force Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration

More information

Financial Disclosure. Objectives 9/24/2018

Financial Disclosure. Objectives 9/24/2018 Hemorrhage and Transfusion Adjuncts in the Setting of Damage Control Joseph Cuschieri, MD FACS Professor of Surgery, University of Washington Adjunct Professor of Orthopedics and Neurosurgery, University

More information

High Risk + Challenging Trauma Cases. Hawaii. Topics 1/27/2014. David Thompson, MD, MPH. Head injury in the anticoagulated patient.

High Risk + Challenging Trauma Cases. Hawaii. Topics 1/27/2014. David Thompson, MD, MPH. Head injury in the anticoagulated patient. High Risk + Challenging Trauma Cases David Thompson, MD, MPH Hawaii Topics Head injury in the anticoagulated patient Shock recognition Case 1: Head injury HPI: 57 yo male w/ PMH atrial fibrillation, on

More information

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell

Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from

More information

ADMINISTRATIVE CLINICAL Page 1 of 6

ADMINISTRATIVE CLINICAL Page 1 of 6 ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation

More information

Trauma Alert Step 2 Additions

Trauma Alert Step 2 Additions Trauma Alert Step 2 Additions MANGLED, DEGLOVED OR PULSELESS EXTREMITY PELVIC INJURY WITH HIGH-RISK MECHANISM OF INJURY Many thanks to Paramedic FTO Justin Bramlette for assembling this training presentation

More information

UPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY. Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center

UPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY. Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center UPDATE OF NEUROCRITICAL CARE PHARMACOTHERAPY Vera Wilson, PharmD, BCPS Emergency Services Clinical Pharmacy Specialist Johnson City Medical Center DISCLOSURE STATEMENT OF FINANCIAL INTEREST I, Vera Wilson,

More information

Everything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science

Everything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science Everything Your Pharmacist Wished You Knew About Anticoagulant Reversal Darrel W. Hughes, Pharm.D., BCPS University Health System & UT Health Science Center at San Antonio Department of Pharmacotherapy

More information

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting

More information

Intracranial Hemorrhage. Objectives. What Do Need to Know?

Intracranial Hemorrhage. Objectives. What Do Need to Know? Intracranial Hemorrhage What Do Need to Know? Kerry Brega, MD Associate Professor of Neurosurgery University of Colorado Objectives Know the common types of ICH. Know how they can be differentiated. Know

More information

Dr Micheal Looney Consultant Anaesthetist Connolly Hospital Blanchardstown. To Delay or Not to Delay Hip Fracture Surgery

Dr Micheal Looney Consultant Anaesthetist Connolly Hospital Blanchardstown. To Delay or Not to Delay Hip Fracture Surgery Dr Micheal Looney Consultant Anaesthetist Connolly Hospital Blanchardstown To Delay or Not to Delay Hip Fracture Surgery "You may delay, but time will not, and lost time is never found again." Benjamin

More information

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS

Afib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial

More information

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center

The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to

More information

Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017

Reversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately

More information

Professional Practice Minutes December 7, 2016

Professional Practice Minutes December 7, 2016 Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon

More information

Introduction. Blood Pressure

Introduction. Blood Pressure Introduction Spontaneous intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality worldwide [1]. Of a number of factors that have been linked to ICH (e.g., higher rates in Asians and

More information

Direct Oral Anticoagulants An Update

Direct Oral Anticoagulants An Update Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what

More information

Treatment with Rivaroxaban Xarelto

Treatment with Rivaroxaban Xarelto Treatment with Rivaroxaban Xarelto Anticoagulation Clinic This handout explains the medicine rivaroxaban, a drug that helps prevent blood clots. What is rivaroxaban? Rivaroxaban (brand name Xarelto) is

More information

Multidisciplinary Geriatric Trauma Care Guideline

Multidisciplinary Geriatric Trauma Care Guideline Multidisciplinary Geriatric Trauma Care Background Traumatic injury in the geriatric population is increasing in prevalence and is associated with higher mortality and complication rates comparted to younger

More information

Treatment with Apixaban Eliquis

Treatment with Apixaban Eliquis Treatment with Apixaban Eliquis Anticoagulation Clinic 416-530-6000 ext 3477 This handout explains the medicine rivaroxaban, a drug that helps prevent blood clots. What is apixaban? Apixaban (brand name

More information

Anticoagulants: Agents, Pharmacology and Reversal

Anticoagulants: Agents, Pharmacology and Reversal Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University

More information

Emergent Anticoagulation Reversal

Emergent Anticoagulation Reversal U N C M E D I C A L C E N T E R G U I D E L I N E Emergent Anticoagulation Reversal I. PURPOSE: The purpose of these instructions is to provide guidelines for the reversal of or management of bleeding

More information

Prothrombin Complex Concentrate- Octaplex. Octaplex

Prothrombin Complex Concentrate- Octaplex. Octaplex Prothrombin Complex Concentrate- Concentrated Factors Prothrombin Complex Concentrate (PCC) 3- factor (factor II, IX, X) 4-factor (factors II, VII, IX, X) Activated 4-factor (factors II, VIIa, IX, X) Coagulation

More information

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016 Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015

More information

UW MEDICINE PATIENT EDUCATION. Treating Blood Clots. What is a blood clot? DRAFT

UW MEDICINE PATIENT EDUCATION. Treating Blood Clots. What is a blood clot? DRAFT UW MEDICINE PATIENT EDUCATION Treating Blood Clots About deep vein thrombosis (DVT) and pulmonary embolism (PE) and how they are treated This handout explains blood clots, their symptoms, and how they

More information

Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults

Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients

More information

Lovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto

Lovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy

More information

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients

More information

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA

INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular

More information

ALL BLEEDING STOPS EVENTUALLY! PATRICK C. CULLINAN, DO FCCM, FACOI, FACOEP SAN ANTONIO, TX

ALL BLEEDING STOPS EVENTUALLY! PATRICK C. CULLINAN, DO FCCM, FACOI, FACOEP SAN ANTONIO, TX ALL BLEEDING STOPS EVENTUALLY! PATRICK C. CULLINAN, DO FCCM, FACOI, FACOEP SAN ANTONIO, TX NO DISCLOSURES! OBJECTIVES Discuss different types of DOACs Discuss the pharmacokinetics of the DOACs Discuss

More information

Coagulation, Haemostasis and interpretation of Coagulation tests

Coagulation, Haemostasis and interpretation of Coagulation tests Coagulation, Haemostasis and interpretation of Coagulation tests Learning Outcomes Indicate the normal ranges for routine clotting screen and explain what each measurement means Recognise how to detect

More information

Anticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar

Anticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for

More information

About Blood Clots and How to Treat Them

About Blood Clots and How to Treat Them PATIENT & CAREGIVER EDUCATION About Blood Clots and How to Treat Them This information describes what a blood clot is and how it is treated. About Blood Clots When you have a cut or an injury, your blood

More information

Chapter 1 The Reversing Agents

Chapter 1 The Reversing Agents Available Strategies to Reverse Anticoagulant Medications Michael L. Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Objectives: Describe the pharmacological agents

More information

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology

Challenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the

More information

Chapter 1 Introduction

Chapter 1 Introduction Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep

More information

True/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran.

True/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran. Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or

More information

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation

Oral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe

More information

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL

ADVOCATE HEALTHCARE GUIDELINE FOR ANTITHROMBOTIC REVERSAL Minimal clinical evidence exists to support the efficacy of nonspecific procoagulant therapies that promote thrombin formation and antifibrinolytics in the setting of antithrombotic-related bleeding. Hemostatic

More information

Bleeding, Coagulopathy, and Thrombosis in the Injured Patient

Bleeding, Coagulopathy, and Thrombosis in the Injured Patient Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial

More information

Global Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017

Global Anticoagulants Market: Size, Trends & Forecasts ( ) April 2017 Global Anticoagulants Market: Size, Trends & Forecasts (2017-2021) April 2017 Global Anticoagulants Market Scope of the Report The report entitled Global Anticoagulants Market: Size, Trends & Forecasts

More information

VENOUS THROMBOEMBOLISM PHARMACOLOGY. University of Hawai i Hilo DNP Program NURS 603 Advanced Clinical Pharmacology Danita Narciso Pharm D

VENOUS THROMBOEMBOLISM PHARMACOLOGY. University of Hawai i Hilo DNP Program NURS 603 Advanced Clinical Pharmacology Danita Narciso Pharm D VENOUS THROMBOEMBOLISM PHARMACOLOGY University of Hawai i Hilo DNP Program NURS 603 Advanced Clinical Pharmacology Danita Narciso Pharm D LEARNING OBJECTIVES Know what factors anticoagulant medications

More information

THROMBOTIC DISORDERS: The Final Frontier

THROMBOTIC DISORDERS: The Final Frontier THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.

More information

Use of Anticoagulant Reversal Agents

Use of Anticoagulant Reversal Agents Use of Anticoagulant Reversal Agents Lori Shutter, MD shutterla@upmc.edu Vice Chair of Education Director, Neurocritical Care Program Professor, Critical Care Medicine, Neurology & Neurosurgery University

More information

Hit head, on blood thinner-wife wants CT. Will Davies June 2014

Hit head, on blood thinner-wife wants CT. Will Davies June 2014 Hit head, on blood thinner-wife wants CT Will Davies June 2014 Selection of Adults with Head Injury for CT Scan Early management of head injury: summary of updated NICE guidance. Hodgkinson S, Pollit V,

More information

Reducing the Use of Reversal Agents in a Community Hospital

Reducing the Use of Reversal Agents in a Community Hospital 4//0 Objectives Reducing the Use of Reversal Agents in a Community Hospital Maria Paulina Duarte, PharmD PGY- Pharmacy Resident Mercy Hospital, A Campus of Plantation General Hospital Review the appropriate

More information

Geriatric (Orthopaedic) Trauma

Geriatric (Orthopaedic) Trauma Geriatric (Orthopaedic) Trauma Brian Buck, DO March 3, 2017 31st Annual Geriatric Conference Pearls of Geriatric Care Do not regret growing older. It is a privilege denied to most Overview East Guidelines

More information

Individualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE

Individualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Goals. Geriatric Trauma. What s the impact Erlanger Trauma Symposium

Goals. Geriatric Trauma. What s the impact Erlanger Trauma Symposium Geriatric Trauma William S. Havron III MD Assistant Professor of Surgery University of Oklahoma Goals Realize the impact of injuries in the ageing population Identify the pitfalls associated with geriatric

More information

Discuss the role of idarucizumab for the management of bleeding associated with dabigatran

Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or

More information

Challenges in Coagulation

Challenges in Coagulation Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from

More information

Hot Topics: Transitions of Care

Hot Topics: Transitions of Care Our quarterly newsletter is a great way to stay up-to-date on emerging clinical information, medication safety issues, and Larkin s Hospital medication policies and procedures. Hot Topics: Transitions

More information

Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring

Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring Oral Factor Xa Inhibitors and Clinical Laboratory Monitoring MELISSA L. WHITE ABSTRACT Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications.

More information

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS

NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address

More information

Content 1. Relevance 2. Principles 3. Manangement

Content 1. Relevance 2. Principles 3. Manangement Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark

More information

Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient

Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient Leading the Charge in Anticoagulation Reversal: Benefits, Risks, and Key Factors in Application to the Traumatically Injured Patient Emily Hutchison, PharmD BCPS Clinical Pharmacy Specialist, Trauma/Adult

More information

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA

More information

KCS Congress: Impact through collaboration

KCS Congress: Impact through collaboration Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact

More information

Aspirin versus pradaxa

Aspirin versus pradaxa Search Search Aspirin versus pradaxa 14-12-2012 Dabigatran (Pradaxa): Good news on safety but caution still warranted. the risk of bleeding versus the risk. (Aspirin and other inhibitors of. 15-12-2008

More information

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital

ANTICOAGULANTS AND HIP FRACTURE SURGERY. Jon Antrobus Anaesthetist Borders General Hospital ANTICOAGULANTS AND HIP FRACTURE SURGERY Jon Antrobus Anaesthetist Borders General Hospital Anticoagulation is common amongst the hip fracture patient population (6-10%) Anticoagulation signifies co-morbidity

More information

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet

More information

Updates in Atrial Fibrillation

Updates in Atrial Fibrillation Updates in Atrial Fibrillation Michael Curley, MD Cardiac Electrophysiologist Wheaton Franciscan Medical Group #1 Most common heart rhythm disturbance 1 in 4 Americans over 40 will be diagnosed 3,500,000

More information

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs)

Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October

More information

Oral Anticoagulation Drug Class Prior Authorization Protocol

Oral Anticoagulation Drug Class Prior Authorization Protocol Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Plavix eliquis and aspirin

Plavix eliquis and aspirin Plavix eliquis and aspirin The Borg System is 100 % Plavix eliquis and aspirin 273 medications are known to interact with Plavix. Includes amlodipine, aspirin, Aspirin Low Strength ( aspirin ). Eliquis

More information

Appendix 3 PCC Warfarin Reversal

Appendix 3 PCC Warfarin Reversal Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin

More information

Mabel Labrada, MD Miami VA Medical Center

Mabel Labrada, MD Miami VA Medical Center Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and

More information

Nanik Hatsakorzian Pharm.D/MPH

Nanik Hatsakorzian Pharm.D/MPH Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome

More information

Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants

Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million

More information

Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society

Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society Coumadin (Warfarin) Does this medication need ongoing monitoring of blood clotting times? Yes.

More information

Post-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose.

Post-procedure dose ok after hours. 12 hours (q 24h dosing only) assuming surgical hemostasis; second dose 24 hours after first dose. Medication Time to wait after last dose Post-procedure dose ok after hours Can pull catheter hours after last dose Can give next dose hours after pulling catheter Enoxaparin (Lovenox) Prophylactic dose

More information

Managing Perioperative Anticoagulation. Edie Shen MD

Managing Perioperative Anticoagulation. Edie Shen MD Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)

More information

a. A pharmacist may order a baseline SCr per protocol

a. A pharmacist may order a baseline SCr per protocol UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin

More information

This quiz is being published on behalf of the Education Committee of the SNACC.

This quiz is being published on behalf of the Education Committee of the SNACC. Shobana Rajan, M.D. Staff Anesthesiologist, Cleveland Clinic, Cleveland, Ohio Quiz team; Shaheen Shaikh, M.D; Suneeta Gollapudy,M.D; Verghese Cherian, M.D This quiz is being published on behalf of the

More information

Clinical issues which drug for which patient

Clinical issues which drug for which patient Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest

More information

Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES

Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,

More information

A Cascade of Updates: Hot Topics in Anticoagulation

A Cascade of Updates: Hot Topics in Anticoagulation A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate

More information

Prostate Biopsy Alerts

Prostate Biopsy Alerts Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table

More information

A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention

A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention This handout is a supplemental resource to an educational video activity released on Medscape

More information

Saman Arbabi M.D., M.P.H., F.A.C.S. Kathleen O'Connell M.D. Bryce Robinson M.D., M.S., F.A.C.S., F.C.C.M

Saman Arbabi M.D., M.P.H., F.A.C.S. Kathleen O'Connell M.D. Bryce Robinson M.D., M.S., F.A.C.S., F.C.C.M Form "EAST Multicenter Study Proposal" Study Title Primary investigator / Senior researcher Email of Primary investigator / Senior researcher Co-primary investigator Are you a current member of EAST? If

More information

Razvana Akbar Anticoagulation Pharmacist LTH

Razvana Akbar Anticoagulation Pharmacist LTH Razvana Akbar Anticoagulation Pharmacist LTH Platelet function Drugs affecting Coagulation; Anti-platelet drugs Anticoagulants Oral anticoagulants Parenteral anticoagulants Drugs affecting Haemoglobin

More information

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures

Hemostasis. PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Hemostasis PHYSIOLOGICAL BLOOD CLOTTING IN RESPONSE TO INJURY OR LEAK no disclosures Disorders of Hemostasis - Hemophilia - von Willebrand Disease HEMOPHILIA A defect in the thrombin propagation phase

More information

Disclosure / Conflict of Interest. None

Disclosure / Conflict of Interest. None Disclosure / Conflict of Interest None Objectives Epidemiology and demographics of injury and emergency surgery in the elderly Anatomic and physiology changes in the context of surgical disease in the

More information

Head injury in children

Head injury in children Head injury in children Michael Kim, MD Department of Emergency Medicine University of Wisconsin- Madison #1 cause of death and disability Bimodal distribution 62,000 hospitalization 564,000 ED visits

More information

Razvana Akbar Anticoagulation Pharmacist LTH

Razvana Akbar Anticoagulation Pharmacist LTH Razvana Akbar Anticoagulation Pharmacist LTH Platelet function Drugs affecting Coagulation; Anti-platelet drugs Anticoagulants Oral anticoagulants Parenteral anticoagulants Drugs affecting Haemoglobin

More information

New Anticoagulants Therapies

New Anticoagulants Therapies New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations

More information

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015

Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support

More information

Boehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017

Boehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017 Boehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017 Dr André Peeters Service de Neurologie Cliniques Universitaires Saint-Luc / U.C.L. 1200 BRUXELLES Introduction 1. Aim NOACS

More information

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture

Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Consensus Statement for Management of Anticoagulants and Antiplatelet drugs in Patients with Hip Fracture Patients with hip fractures should be operated on within 36 hours of presentation wherever possible.

More information

The effect of the direct oral anticoagulants (DOACs) on haemostasis tests.

The effect of the direct oral anticoagulants (DOACs) on haemostasis tests. The effect of the direct oral anticoagulants (DOACs) on haemostasis tests. Emmanuel J Favaloro, Haematology, ICPMR, Pathology West, Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital (with

More information

Disclosures. Learning Objectives. Financial: none. Off label discussion: Recommendations in lieu of data

Disclosures. Learning Objectives. Financial: none. Off label discussion: Recommendations in lieu of data Kathryn Hassell, MD Professor of Medicine, Division of Hematology University of Colorado Denver Disclosures Financial: none Off label discussion: Prothormbin complex concentrates for DOAC reversal Use

More information